concept

HIF

Entity Detail — Knowledge Graph Node

Understanding Entity Pages

This page aggregates everything SciDEX knows about HIF: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.

1364Connections

11Hypotheses

1Analyses

50Outgoing

50Incoming

1Experiments

1Debates

Summary

HIF is a concept in neurodegeneration research. Key relationships include: activates, interacts with, therapeutic target. Associated with AD, ALI, ALS. Connected to 636 entities in the SciDEX knowledge graph.

View on Wiki →

No AI portrait yet

💡 Concept Info

Name	HIF
Key Genes/Proteins	ABCA7, ABCB1, ABCD3, ABCG2, ACETYL-COA, ACLY
Related Diseases	AD, Aging
Related Pathways	Akt
Linked Hypotheses	7 hypotheses

Wiki Pages (12)

Knowledge base pages for this entity

Canonical Page

Pathway Diagram

graph TD
    HIF["HIF"]
    HIF -->|"activates"| ALS["ALS"]
    HIF -->|"activates"| Carcinoma["Carcinoma"]
    HIF -->|"activates"| Cancer["Cancer"]
    HIF -->|"interacts"| Alzheimer["Alzheimer"]
    HIF -->|"interacts"| Frontotemporal_Dementia["Frontotemporal Dementia"]
    HIF -->|"interacts"| Dementia["Dementia"]
    HIF -->|"interacts"| Cardiovascular["Cardiovascular"]
    HIF -->|"interacts"| Parkinson["Parkinson"]
    HIF -->|"activates"| Tumor["Tumor"]
    VHL["VHL"] -->|"regulates"| HIF
    BCL2L11["BCL2L11"] -->|"interacts"| HIF
    DNA["DNA"] -->|"interacts"| HIF
    NIX["NIX"] -->|"interacts"| HIF
    HIF1["HIF1"] -->|"interacts"| HIF
    RB1["RB1"] -->|"interacts"| HIF
    NLRP3["NLRP3"] -->|"interacts"| HIF
    PARKINSON["PARKINSON"] -->|"interacts"| HIF
    FMR1["FMR1"] -->|"interacts"| HIF
    RB1CC1["RB1CC1"] -->|"interacts"| HIF

Outgoing (911)

Target	Relation	Type	Str
GENES	activates	gene	1.00
Mtor	activates	pathway	1.00
Inflammation	activates	disease	1.00
Tumor	activates	disease	1.00
Als	activates	disease	1.00
Pi3K/Akt	activates	pathway	1.00
CANCER	activates	gene	1.00
Glycolysis	activates	pathway	1.00
MTOR	activates	gene	1.00
Cancer	activates	disease	1.00
INFLAMMATION	activates	gene	1.00
AKT	activates	gene	1.00
MYC	activates	gene	1.00
Cancer	regulates	disease	0.95
Carcinoma	activates	disease	0.95
Cancer	therapeutic_target	disease	0.95
oxidative stress response	participates_in	pathway	0.90
CANCER	regulates	gene	0.90
Oxidative Phosphorylation	activates	pathway	0.90
MITOCHONDRIA	activates	gene	0.90
Inflammation	regulates	disease	0.85
iron homeostasis	regulates	process	0.85
Tumor	therapeutic_target	disease	0.85
unfolded protein response	participates_in	pathway	0.80
PI3K-AKT-mTOR signaling	participates_in	pathway	0.80
apoptosis pathway	participates_in	pathway	0.80
hypoxia response	regulates	pathway	0.80
microglia	expressed_in	cell_type	0.80
neural stem cells	activates	cell_type	0.80
Angiogenesis	activates	pathway	0.80
Oxidative Stress	inhibits	pathway	0.80
Apoptosis	activates	pathway	0.80
CANCER	therapeutic_target	gene	0.80
Mapk	activates	pathway	0.80
AMPK	activates	gene	0.80
RAS	activates	gene	0.80
Glycolysis	regulates	pathway	0.80
Epigenetic	activates	pathway	0.80
MICROGLIA	activates	gene	0.80
Lipid Metabolism	regulates	pathway	0.80
Mtor	associated_with	pathway	0.80
NF-ΚB	activates	gene	0.80
Nf-Κb	activates	pathway	0.80
MTOR	associated_with	gene	0.80
Oxidative Stress	therapeutic_target	pathway	0.80
Autophagy	inhibits	pathway	0.80
Stem Cell	inhibits	pathway	0.80
Cardiovascular	therapeutic_target	disease	0.75
Als	inhibits	disease	0.75
Infection	activates	disease	0.75

Incoming (453)

Source	Relation	Type	Str
PI3K	activates	gene	1.00
VHL	degrades	protein	0.95
OXIDATIVE STRESS	therapeutic_target	gene	0.80
VHL	activates	gene	0.80
OXIDATIVE STRESS	inhibits	gene	0.80
STAT3	activates	gene	0.80
PI3K	associated_with	gene	0.80
STAT3	therapeutic_target	gene	0.80
VHL	regulates	gene	0.72
PTEN	activates	gene	0.70
CD44	therapeutic_target	gene	0.70
SLC7A11	inhibits	gene	0.70
NAD	activates	gene	0.70
INFLAMMATION	activates	gene	0.70
PARKINSON'S DISEASE	therapeutic_target	gene	0.70
ERK	inhibits	gene	0.70
APOPTOSIS	implicated_in	gene	0.70
ATG5	regulates	gene	0.70
HK2	activates	gene	0.70
APOPTOSIS	therapeutic_target	gene	0.70
AKT1	therapeutic_target	gene	0.70
APOPTOSIS	activates	gene	0.70
STING1	interacts_with	gene	0.60
NLRP3	interacts_with	gene	0.60
NIX	interacts_with	gene	0.60
DDIT3	interacts_with	gene	0.60
EMD	interacts_with	gene	0.60
OPTN	interacts_with	gene	0.60
ERN1	interacts_with	gene	0.60
PRKN	interacts_with	gene	0.60
MITOPHAGY	interacts_with	gene	0.60
RB1	interacts_with	gene	0.60
PINK1	interacts_with	gene	0.60
DEMENTIA	interacts_with	gene	0.60
MAPK8	interacts_with	gene	0.60
PRESENILIN	interacts_with	gene	0.60
ALZHEIMER DISEASE	interacts_with	gene	0.60
CAT	interacts_with	gene	0.60
ALZHEIMER	interacts_with	gene	0.60
UBIQUITIN	interacts_with	gene	0.60
ROS	interacts_with	gene	0.60
SQSTM1	interacts_with	gene	0.60
ERK	associated_with	gene	0.60
GAIN	activates	gene	0.60
VEGFA	therapeutic_target	gene	0.60
JAK2	therapeutic_target	gene	0.60
PHAGOCYTOSIS	causes	gene	0.60
EPAS1	interacts_with	gene	0.60
LC3	interacts_with	gene	0.60
KRAS	activates	gene	0.60

Targeting Hypotheses (11)

Hypotheses where this entity is a therapeutic target

Hypothesis	Score	Disease	Analysis
Targeting SASP-Complement Amplification Through HIF-1α Downs	0.793	neurodegeneration	What molecular mechanism causes VCP muta
INPP5D (SHIP1) Inhibition to Shift Microglial Polarization	0.758	neurodegeneration	TREM2 agonism vs antagonism in DAM micro
Metabolic Rewiring via SPP1-Induced HIF1α Glycolytic Shift	0.620	neuroinflammation	What molecular mechanisms mediate SPP1-i
Microglial Metabolic Trained Immunity via mTOR-HIF1α Axis	0.620	developmental neurobiology	Do perinatal immune challenges create pe
ALS-Associated G3BP1 Mutations Shift Phase Separation Equili	0.610	neurodegeneration	How do disease-associated mutations in G

HIF1A stabilization lowers the activation threshold of circa	0.609	neuroinflammation	Do microglia actually switch between gly
Intermittent HBOT (2.0 ATA, 60 min, 3x/week) suppresses NLRP	0.590	neurodegeneration	What are the optimal oxygen pressure, du
Microglial Replacement and Ontogeny Shift	0.580	developmental neurobiology	Do perinatal immune challenges create pe
Dysregulated microglial glycolysis via HIF1α activation shif	0.520	neurodegeneration	Synaptic pruning by microglia in neurode
Shift AQP4 Isoform/OAP Assembly Toward Clearance-Competent A	0.500	neurodegeneration	How can AQP4 be effectively targeted the
Moderate hyperoxia (1.5-2.0 ATA) optimally stabilizes HIF-1α	0.470	neurodegeneration	What are the optimal oxygen pressure, du

Mentioning Analyses (1)

Scientific analyses that reference this entity

What molecular mechanism causes VCP mutations to trigger aberrant HIF-1α activat

neurodegeneration | 2026-04-13 | 2 hypotheses Top: 0.793

Experiments (1)

Experimental studies targeting or related to this entity

Experiment	Type	Disease	Score	Feasibility	Model	Status	Est. Cost
Single-cell RNA sequencing analysis of human atherosclerotic plaques	exploratory	Atherosclerosis	0.900	0.00	Human atherosclerotic plaque s	proposed	N/A

Related Papers (8)

Scientific publications cited in analyses involving this entity

Title & PMID	Authors	Journal	Year
PLCG2 signaling and genetic resilience in Alzheimer's disease. [PMID:41888907]	Tsai AP, Martin AK, Mi A, Yeh AE, Ramire	Molecular neurodegeneration	2026
Single-cell sequencing analysis and machine learning model reveal aberrant TIM-3 [PMID:41580850]	Xu Z, Chen M, Liang F, Song S, Lei J et	J Transl Med	2026
Repression of RIPK1 kinase by INPP5D inhibits expression of diverse proinflammat [PMID:41633359]	Xie X, Liu J, Liang W, Zhang Y, Gong X e	Immunity	2026
INPP5D/SHIP1-mediated immunometabolic remodeling of renal monocytes in idiopathi [PMID:41853261]	Dai H, Liu B, Rui H, Yang L, Jiang H et	Front Immunol	2026
PLCG2 signaling and genetic resilience in Alzheimer's disease. [PMID:41888907]	Tsai AP, Martin AK, Mi A, Yeh AE, Ramire	Mol Neurodegener	2026
SHIP-1 adapter functions mediate recruitment of FCRL1 to the BCR and inhibition [PMID:41968726]	Wolfe MM, Tallon Arranz R, Zenni EL, Wil	Immunohorizons	2026
Repression of RIPK1 kinase by INPP5D inhibits expression of diverse proinflammat [PMID:41633359]	Xie X, Liu J, Liang W, Zhang Y, Gong X,	Immunity	2026
Single-cell sequencing analysis and machine learning model reveal aberrant TIM-3 [PMID:41580850]	Xu Z, Chen M, Liang F, Song S, Lei J, Hu	Journal of translational medic	2026

Debates (1)

Multi-agent debates referencing this entity

The study shows VCP-mutant astrocytes exhibit hypoxia response activation withou

closed · Rounds: 4 · Score: 0.78 · 2026-04-13

HIF

Understanding Entity Pages

Summary

Wiki Pages (12)

HIF-1α Stabilization Therapy for Neurodegeneration

HIF1AN — Hypoxia Inducible Factor 1 Subunit Alpha Inhibitor

HIF/Hypoxia Signaling in Parkinson's Disease

HIF/Hypoxia Signaling in Parkinson's Disease

HIF-1α (Hypoxia-Inducible Factor 1-Alpha)

HIF Signaling in Neurodegeneration

Parkinson's Disease HIF/Hypoxia Signaling Therapy Companies

HIF Therapeutics for Neurodegeneration — Investment Landscape Analysis

HIF-1α Protein

HIF-1α Protein - Hypoxia Inducible Factor 1-alpha

HIF-1α Stabilization Therapy

HIF1A Gene - Hypoxia Inducible Factor 1 Subunit Alpha